Almirall revenues slide by 11.5% in 'very challenging' half

Revenues at Almirall (ALM: MC), Spain’s largest drugmaker, were 11.5% lower in the first half of 2017 than in the previous year, its latest financial figures show.

The 378.9 million euros ($441 million) total revenue figure compares to 428.1 million euros for the first six months of 2016, with gross profit sliding by 22.3% to 212.2 million euros.

The drop in earnings before interest, tax, depreciation and amortization (EBITDA) was 52.6%, slipping to 58.6 million euros.